DK1994055T3 - Anti-5t4-antistoffer og anvendelser deraf - Google Patents

Anti-5t4-antistoffer og anvendelser deraf

Info

Publication number: DK1994055T3
Authority: DK; Denmark
Prior art keywords: antibodies; applications
Prior art date: 2006-03-10

Application number

DK07758256.7T

Other languages

English (en)

Inventor

Erwin R Boghaert

Nitin K Damle

Philip Ross Hamann

Kiran Khandke

Arthur Kunz

Kimberly A Marquette

Davinder Gill

Lioudmila Tchistiakova

Kodangattil Sreekumar

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-10

Filing date

2007-03-09

Publication date

2014-08-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38445207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1994055(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-03-09 Application filed by Wyeth Llc filed Critical Wyeth Llc

2014-08-25 Application granted granted Critical

2014-08-25 Publication of DK1994055T3 publication Critical patent/DK1994055T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Toxicology (AREA)
Zoology (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK07758256.7T 2006-03-10 2007-03-09 Anti-5t4-antistoffer og anvendelser deraf DK1994055T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US78134606P	2006-03-10	2006-03-10
US89124807P	2007-02-23	2007-02-23
PCT/US2007/063685 WO2007106744A2 (en)	2006-03-10	2007-03-09	Anti-5t4 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
DK1994055T3 true DK1994055T3 (da)	2014-08-25

Family

ID=38445207

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK07758256.7T DK1994055T3 (da)	2006-03-10	2007-03-09	Anti-5t4-antistoffer og anvendelser deraf
DK11154157.9T DK2368914T3 (da)	2006-03-10	2007-03-09	Anti-5T4-antistoffer og anvendelser deraf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK11154157.9T DK2368914T3 (da)	2006-03-10	2007-03-09	Anti-5T4-antistoffer og anvendelser deraf

Country Status (29)

Country	Link
US (5)	US8044178B2 (da)
EP (3)	EP1994055B1 (da)
JP (1)	JP5523824B2 (da)
KR (2)	KR101443752B1 (da)
CN (1)	CN101437850B (da)
AR (1)	AR059809A1 (da)
AU (1)	AU2007226696C1 (da)
BR (1)	BRPI0708771B8 (da)
CA (1)	CA2645097C (da)
CR (1)	CR10273A (da)
DK (2)	DK1994055T3 (da)
EC (1)	ECSP088733A (da)
ES (2)	ES2712942T3 (da)
GT (1)	GT200800181A (da)
IL (2)	IL193986A (da)
MX (1)	MX2008011492A (da)
MY (1)	MY148763A (da)
NO (1)	NO20083891L (da)
NZ (2)	NZ571208A (da)
PA (1)	PA8718601A1 (da)
PE (1)	PE20080119A1 (da)
PL (1)	PL1994055T3 (da)
PT (1)	PT1994055E (da)
SA (1)	SA07280101B1 (da)
SG (1)	SG170091A1 (da)
SI (1)	SI1994055T1 (da)
TW (2)	TWI409277B (da)
WO (1)	WO2007106744A2 (da)
ZA (1)	ZA200808075B (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2634783A1 (en) *	2005-12-23	2008-05-08	Board Of Regents Of The University Of Texas System	Anti-hyperproliferative therapies targeting hdgf
BRPI0708771B8 (pt) *	2006-03-10	2021-05-25	Wyeth Corp	anticorpos anti-5t4, conjugado de fármaco/ anticorpo para liberação de fármaco, usos dos mesmos e ácido nucléico isolado codificando uma região variável de cadeias pesada e leve anti-5t4
WO2008027986A2 (en)	2006-09-01	2008-03-06	Therapeutic Human Polyclonals, Inc.	Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
CA2754610C (en)	2009-03-27	2015-05-05	Marc Isaac Damelin	Tumor-initiating cells and methods for using same
GB0918383D0 (en)	2009-10-20	2009-12-02	Cancer Rec Tech Ltd	Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
BR112012025568A2 (pt)	2010-04-07	2017-03-28	Abbvie Inc	proteínas de ligação ao tnf-<244>.
WO2012109282A2 (en) *	2011-02-07	2012-08-16	Agamin Pharmaceuticals, Llc	Methods and systems for treating or preventing pregnancy-related hypertensive disorders
ES2596194T3 (es) *	2011-04-01	2017-01-05	Wyeth Llc	Conjugados de anticuerpo-fármaco
CA2845884A1 (en)	2011-08-22	2013-02-28	Cangene Corporation	Clostridium difficile antibodies
WO2013041687A1 (en)	2011-09-23	2013-03-28	Amgen Research (Munich) Gmbh	Bispecific binding molecules for 5t4 and cd3
WO2013068874A1 (en)	2011-11-11	2013-05-16	Pfizer Inc.	Antibody-drug conjugates
JP6254951B2 (ja)	2012-01-24	2017-12-27	ファイザー・インク	哺乳類の対象における５ｔ４陽性循環腫瘍細胞を検出するための方法および５ｔ４陽性がんの診断の方法
MX2015007446A (es)	2012-12-12	2015-12-07	Vasculox Inc	Anticuerpos terapeuticos para cd47.
US9221908B2 (en)	2012-12-12	2015-12-29	Vasculox, Inc.	Therapeutic CD47 antibodies
WO2014137931A1 (en) *	2013-03-06	2014-09-12	Imaginab, Inc.	Antigen binding constructs to 5t4
EP2968536B1 (en) *	2013-03-13	2023-06-28	The United States of America, as represented by The Secretary, Department of Health and Human Services	Methods for modulating chemotherapeutic cytotoxicity
EP3010939A2 (en) *	2013-06-17	2016-04-27	Asana BioSciences, LLC	5t4-targeted immunofusion molecule and methods
ES2726850T3 (es)	2013-10-11	2019-10-09	Mersana Therapeutics Inc	Conjugados de proteína-polímero-fármaco
PL3054992T3 (pl)	2013-10-11	2020-01-31	Asana Biosciences, Llc	Koniugaty białko-polimer-lek
EP3065780A1 (en)	2013-11-04	2016-09-14	Pfizer Inc.	Anti-efna4 antibody-drug conjugates
WO2015155345A1 (en) *	2014-04-11	2015-10-15	Medimmune Limited	Antibodies and antibody-drug conjugates
JP6517240B2 (ja)	2014-05-22	2019-05-22	シントン・バイオファーマシューティカルズ・ビー．ブイ．ＳｙｎｔｈｏｎＢｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓＢ．Ｖ．	抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるａｄｃ
NZ726520A (en)	2014-05-29	2018-12-21	Macrogenics Inc	Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
BR112017001821A2 (pt)	2014-07-29	2017-11-21	Cellectis	receptores de antígenos quiméricos específicos de ror1 (ntrkr1) para imunoterapia de câncer
WO2016016343A1 (en)	2014-07-31	2016-02-04	Cellectis	Ror1 specific multi-chain chimeric antigen receptor
EP3189073B2 (en)	2014-09-04	2025-06-11	Cellectis	Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
US20160251417A1 (en) *	2015-01-22	2016-09-01	Prothena Biosciences Limited	Antibodies recognizing medin
EP3298046B1 (en)	2015-05-20	2025-02-12	Cellectis	Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy
BR112018005322A2 (pt)	2015-09-18	2018-12-11	Arch Oncology, Inc.	anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
EP3184547A1 (en)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg antibodies and methods of use
BR112018010394A8 (pt)	2015-11-24	2019-02-26	Synthon Biopharmaceuticals Bv	anticorpo, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação do anticorpo.
CN106916227B (zh) *	2015-12-24	2019-12-13	凯惠科技发展(上海)有限公司	一种tpbg抗体及其制备方法、其偶联物和应用
WO2018017714A1 (en) *	2016-07-20	2018-01-25	Aerpio Therapeutics, Inc.	HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
EP3529276A4 (en)	2016-10-21	2020-06-17	Arch Oncology, Inc.	CD47 THERAPEUTIC ANTIBODIES
CN108084265B (zh) *	2016-11-23	2021-07-02	复旦大学	特异性结合人的5t4抗原的全人源单域抗体及其应用
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
CN108285487B (zh) *	2017-01-08	2021-02-19	浙江昭华生物医药有限公司	抗5t4抗体-药物偶联物及其应用
EP3585431A4 (en)	2017-02-24	2020-12-16	MacroGenics, Inc.	BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
KR20230166145A (ko)	2017-03-15	2023-12-06	옥스포드 바이오메디카(유케이) 리미티드	방법
WO2018184558A1 (zh) *	2017-04-05	2018-10-11	凯惠科技发展(上海)有限公司	一种人源化抗tpbg抗体及其制备方法、其偶联物和应用
MY200973A (en)	2017-04-11	2024-01-26	Inhibrx Inc	Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
WO2018226795A1 (en) *	2017-06-06	2018-12-13	The Regents Of The University Of California	Humanized anti-n-cadherin antibodies and uses thereof
CA3070272A1 (en)	2017-07-20	2019-01-24	Aptevo Research And Development Llc	Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
EP3717021A1 (en)	2017-11-27	2020-10-07	Mersana Therapeutics, Inc.	Pyrrolobenzodiazepine antibody conjugates
EP3727463A1 (en)	2017-12-21	2020-10-28	Mersana Therapeutics, Inc.	Pyrrolobenzodiazepine antibody conjugates
CN108187065B (zh) *	2017-12-29	2023-04-28	广东众生药业股份有限公司	抗5t4抗体与美登素衍生物dm4偶联复合物及制备方法和用途
MX2020007024A (es)	2018-01-03	2020-10-28	Palleon Pharmaceuticals Inc	Sialidasas humanas recombinantes, proteinas de fusion de sialidasa y metodos para usar las mismas.
EP3765493A2 (en)	2018-03-12	2021-01-20	Genmab A/S	Antibodies
IL323061A (en)	2018-04-11	2025-10-01	Inhibrx Biosciences Inc	Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
CN112789294A (zh)	2018-07-24	2021-05-11	印希比股份有限公司	含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
US11208485B2 (en)	2018-10-11	2021-12-28	Inhibrx, Inc.	PD-1 single domain antibodies and therapeutic compositions thereof
AU2019369340A1 (en)	2018-10-29	2021-05-20	Mersana Therapeutics, Inc.	Cysteine engineered antibody-drug conjugates with peptide-containing linkers
WO2021048423A1 (en)	2019-09-12	2021-03-18	Genmab A/S	Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
CN115380047A (zh)	2020-01-29	2022-11-22	印希比股份有限公司	Cd28单结构域抗体及其多价和多特异性构建体
EP4106813A4 (en)	2020-02-21	2024-03-27	MacroGenics, Inc.	CD137 BINDING MOLECULES AND THEIR USES
US20220288244A1 (en) *	2020-10-22	2022-09-15	Actinium Pharmaceuticals, Inc.	Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
EP4232052A4 (en) *	2020-10-22	2025-08-20	Actinium Pharmaceuticals Inc	COMBINATION OF RADIOMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER
US20220251239A1 (en) *	2020-10-22	2022-08-11	Actinium Pharmaceuticals, Inc.	Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
MX2023008028A (es) *	2021-01-06	2023-08-14	Palleon Pharmaceuticals Inc	Anticuerpos anti-pd-l1 y proteinas de fusion de estos.
AU2023220523A1 (en) *	2022-02-21	2024-09-12	Lepu Biopharma Co., Ltd.	Anti-5t4 antibodies and uses thereof
JP2025537044A (ja)	2022-09-30	2025-11-13	シャンハイドーァノボファーマテックカンパニー，リミティド	ベンザゼピン誘導体、それを含む複合体およびその応用
EP4353220A1 (en) *	2022-10-12	2024-04-17	Pierre Fabre Medicament	Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
CN116715773B (zh) *	2023-02-28	2024-03-01	星奕昂(上海)生物科技有限公司	一种靶向5t4的抗体及其应用
KR20250158033A (ko) *	2023-03-08	2025-11-05	바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드	항-5t4 항체 및 이의 용도
AR132178A1 (es) *	2023-03-22	2025-06-04	Salubris Biotherapeutics Inc	Dominios de unión al antígeno anti-5t4, conjugados anticuerpo-fármaco, y métodos de uso de los mismos
WO2024208145A1 (zh) *	2023-04-03	2024-10-10	非同（成都）生物科技有限公司	抗5t4抗体及其应用
WO2024258870A2 (en)	2023-06-12	2024-12-19	Amgen Inc.	Lymphotoxin beta receptor agonist binding proteins

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196265A (en)	1977-06-15	1980-04-01	The Wistar Institute	Method of producing antibodies
US4671958A (en)	1982-03-09	1987-06-09	Cytogen Corporation	Antibody conjugates for the delivery of compounds to target sites
US6054561A (en)	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
US4970198A (en)	1985-10-17	1990-11-13	American Cyanamid Company	Antitumor antibiotics (LL-E33288 complex)
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5079233A (en)	1987-01-30	1992-01-07	American Cyanamid Company	N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5108912A (en)	1987-01-30	1992-04-28	American Cyanamid Company	Antitumor antibiotics (LL-E33288 complex)
US5037651A (en)	1987-01-30	1991-08-06	American Cyanamid Company	Dihydro derivatives of LL-E33288 antibiotics
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
US5053394A (en)	1988-09-21	1991-10-01	American Cyanamid Company	Targeted forms of methyltrithio antitumor agents
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5869053A (en)	1988-03-04	1999-02-09	Cancer Research Campaign Technology, Ltd.	5T4 antigen from human trophoblasts
EP0403559A1 (en)	1988-03-04	1990-12-27	Cancer Research Campaign Technology Limited	Improvements relating to antigens
KR0162259B1 (ko)	1989-12-05	1998-12-01	아미 펙터	감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
GB9115364D0 (en)	1991-07-16	1991-08-28	Wellcome Found	Antibody
GB9116610D0 (en)	1991-08-01	1991-09-18	Danbiosyst Uk	Preparation of microparticles
US6310185B1 (en)	1994-03-08	2001-10-30	Memorial Sloan Kettering Cancer Center	Recombinant human anti-Lewis Y antibodies
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
ZA955642B (en)	1994-07-07	1997-05-06	Ortho Pharma Corp	Lyophilized imaging agent formulation
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO1997026885A1 (en)	1996-01-23	1997-07-31	The General Hospital Corporation Doing Business As Massachusetts General Hospital	Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors
AU747602B2 (en)	1997-06-04	2002-05-16	Oxford Biomedica (Uk) Limited	Vector
GB2370571B (en)	1998-11-18	2003-05-07	Oxford Biomedica Ltd	A modified 5t4 antigen
GB2378704B (en)	1998-11-18	2003-05-07	Oxford Biomedica Ltd	Uses of 5t4 antigen
CN1298851C (zh)	1998-11-18	2007-02-07	牛津生物医学（英国）有限公司	多肽
US6309633B1 (en)	1999-06-19	2001-10-30	Nobex Corporation	Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
EP1130094A3 (en) *	1999-07-08	2001-11-21	Helix Research Institute	Primers for synthesizing full length cDNA clones and their use
AU2001257577A1 (en)	2000-02-28	2001-09-03	Shearwater Corporation	Water-soluble polymer conjugates of artelinic acid
CA2634294A1 (en)	2000-08-03	2002-02-14	Therapeutic Human Polyclonals, Inc.	Production of humanized antibodies in transgenic animals
WO2002038612A2 (en) *	2000-11-13	2002-05-16	Oxford Biomedica (Uk) Limited	Canine and feline tumour-associated antigen 5t4
WO2002096948A2 (en)	2001-01-29	2002-12-05	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
CA2445898A1 (en)	2001-05-01	2002-12-19	The General Hospital Corporation	Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US7321026B2 (en)	2001-06-27	2008-01-22	Skytech Technology Limited	Framework-patched immunoglobulins
US6997863B2 (en)	2001-07-25	2006-02-14	Triton Biosystems, Inc.	Thermotherapy via targeted delivery of nanoscale magnetic particles
GB0126378D0 (en) *	2001-11-02	2002-01-02	Oxford Biomedica Ltd	Antigen
GB0203419D0 (en) *	2002-02-13	2002-04-03	Oxford Biomedica Ltd	Peptide
US8420353B2 (en)	2002-03-22	2013-04-16	Aprogen, Inc.	Humanized antibody and process for preparing same
TWI438010B (zh)	2002-05-02	2014-05-21	Wyeth Corp	卡奇黴素（ｃａｌｉｃｈｅａｍｉｃｉｎ）衍生物-載體共軛物
AR048098A1 (es)	2004-03-15	2006-03-29	Wyeth Corp	Conjugados de caliqueamicina
CA2571743A1 (en)	2004-06-30	2006-01-12	International Bioimmune Systems, Inc.	Humanized monoclonal antibody 31.1 as an anticancer agent
TW200616662A (en)	2004-09-10	2006-06-01	Wyeth Corp	Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
WO2006042158A2 (en) *	2004-10-05	2006-04-20	Wyeth	Methods and compositions for improving recombinant protein production
BRPI0708771B8 (pt) *	2006-03-10	2021-05-25	Wyeth Corp	anticorpos anti-5t4, conjugado de fármaco/ anticorpo para liberação de fármaco, usos dos mesmos e ácido nucléico isolado codificando uma região variável de cadeias pesada e leve anti-5t4
PT3056203T (pt)	2010-04-21	2018-02-15	Syntarga Bv	Conjugados de análogos de cc-1065 e ligantes bifuncionais
ES2596194T3 (es) *	2011-04-01	2017-01-05	Wyeth Llc	Conjugados de anticuerpo-fármaco

2007
- 2007-03-09 BR BRPI0708771A patent/BRPI0708771B8/pt not_active IP Right Cessation
- 2007-03-09 PA PA20078718601A patent/PA8718601A1/es unknown
- 2007-03-09 EP EP07758256.7A patent/EP1994055B1/en not_active Revoked
- 2007-03-09 DK DK07758256.7T patent/DK1994055T3/da active
- 2007-03-09 WO PCT/US2007/063685 patent/WO2007106744A2/en not_active Ceased
- 2007-03-09 KR KR1020137000307A patent/KR101443752B1/ko not_active Expired - Fee Related
- 2007-03-09 TW TW096108184A patent/TWI409277B/zh not_active IP Right Cessation
- 2007-03-09 SI SI200731486T patent/SI1994055T1/sl unknown
- 2007-03-09 EP EP18213944.4A patent/EP3539989A1/en not_active Withdrawn
- 2007-03-09 MX MX2008011492A patent/MX2008011492A/es active IP Right Grant
- 2007-03-09 AR ARP070100988A patent/AR059809A1/es active IP Right Grant
- 2007-03-09 PT PT77582567T patent/PT1994055E/pt unknown
- 2007-03-09 NZ NZ571208A patent/NZ571208A/en not_active IP Right Cessation
- 2007-03-09 CN CN200780016577XA patent/CN101437850B/zh not_active Expired - Fee Related
- 2007-03-09 ES ES11154157T patent/ES2712942T3/es active Active
- 2007-03-09 PE PE2007000262A patent/PE20080119A1/es active IP Right Grant
- 2007-03-09 DK DK11154157.9T patent/DK2368914T3/da active
- 2007-03-09 TW TW102115071A patent/TWI421257B/zh not_active IP Right Cessation
- 2007-03-09 PL PL07758256T patent/PL1994055T3/pl unknown
- 2007-03-09 CA CA2645097A patent/CA2645097C/en not_active Expired - Fee Related
- 2007-03-09 US US11/684,329 patent/US8044178B2/en not_active Expired - Fee Related
- 2007-03-09 NZ NZ596295A patent/NZ596295A/xx not_active IP Right Cessation
- 2007-03-09 AU AU2007226696A patent/AU2007226696C1/en not_active Ceased
- 2007-03-09 JP JP2009500565A patent/JP5523824B2/ja not_active Expired - Fee Related
- 2007-03-09 EP EP11154157.9A patent/EP2368914B1/en not_active Revoked
- 2007-03-09 MY MYPI20084016A patent/MY148763A/en unknown
- 2007-03-09 ES ES07758256.7T patent/ES2498517T3/es active Active
- 2007-03-09 SG SG201101720-9A patent/SG170091A1/en unknown
- 2007-03-10 SA SA7280101A patent/SA07280101B1/ar unknown
2008
- 2008-09-05 CR CR10273A patent/CR10273A/es not_active Application Discontinuation
- 2008-09-09 IL IL193986A patent/IL193986A/en active IP Right Grant
- 2008-09-10 GT GT200800181A patent/GT200800181A/es unknown
- 2008-09-10 EC EC2008008733A patent/ECSP088733A/es unknown
- 2008-09-11 NO NO20083891A patent/NO20083891L/no not_active Application Discontinuation
- 2008-09-19 ZA ZA2008/08075A patent/ZA200808075B/en unknown
- 2008-10-10 KR KR1020087024914A patent/KR101264216B1/ko not_active Expired - Fee Related
2011
- 2011-08-11 US US13/208,162 patent/US8759495B2/en not_active Expired - Fee Related
2014
- 2014-05-29 US US14/290,345 patent/US20140308302A1/en not_active Abandoned
2015
- 2015-07-30 IL IL240245A patent/IL240245A/en active IP Right Grant
- 2015-12-16 US US14/971,536 patent/US9902771B2/en not_active Expired - Fee Related
2018
- 2018-01-30 US US15/883,759 patent/US20180162937A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR101443752B1 (ko)	2014-09-26
PA8718601A1 (es)	2009-05-15
PL1994055T3 (pl)	2015-02-27
IL240245A (en)	2017-05-29
IL240245A0 (en)	2015-09-24
SI1994055T1 (sl)	2014-08-29
ECSP088733A (es)	2008-10-31
KR20130018980A (ko)	2013-02-25
US8044178B2 (en)	2011-10-25
HK1121473A1 (en)	2009-04-24
US20070231333A1 (en)	2007-10-04
US9902771B2 (en)	2018-02-27
EP1994055B1 (en)	2014-07-02
MY148763A (en)	2013-05-31
SA07280101B1 (ar)	2011-10-03
BRPI0708771B8 (pt)	2021-05-25
EP2368914A1 (en)	2011-09-28
IL193986A0 (en)	2011-08-01
CA2645097A1 (en)	2007-09-20
TW201335189A (zh)	2013-09-01
CN101437850A (zh)	2009-05-20
ES2712942T3 (es)	2019-05-16
US8759495B2 (en)	2014-06-24
JP2009529578A (ja)	2009-08-20
CN101437850B (zh)	2013-10-09
US20160185859A1 (en)	2016-06-30
ZA200808075B (en)	2012-03-28
US20120064600A1 (en)	2012-03-15
TW200804424A (en)	2008-01-16
NO20083891L (no)	2008-12-03
SG170091A1 (en)	2011-04-29
NZ596295A (en)	2013-01-25
WO2007106744A3 (en)	2007-11-29
TWI421257B (zh)	2014-01-01
CA2645097C (en)	2019-09-17
MX2008011492A (es)	2008-09-22
US20180162937A1 (en)	2018-06-14
EP2368914B1 (en)	2019-01-02
AR059809A1 (es)	2008-04-30
US20140308302A1 (en)	2014-10-16
BRPI0708771A2 (pt)	2011-06-14
AU2007226696B2 (en)	2013-08-29
BRPI0708771B1 (pt)	2019-10-22
RU2008137074A (ru)	2010-04-20
AU2007226696C1 (en)	2016-02-04
DK2368914T3 (da)	2019-03-04
PT1994055E (pt)	2014-09-15
WO2007106744A8 (en)	2008-10-02
KR101264216B1 (ko)	2013-05-31
KR20080106345A (ko)	2008-12-04
ES2498517T3 (es)	2014-09-24
JP5523824B2 (ja)	2014-06-18
TWI409277B (zh)	2013-09-21
AU2007226696A1 (en)	2007-09-20
WO2007106744A2 (en)	2007-09-20
GT200800181A (es)	2010-05-25
PE20080119A1 (es)	2008-03-04
NZ571208A (en)	2011-12-22
CR10273A (es)	2008-11-26
EP1994055A2 (en)	2008-11-26
IL193986A (en)	2015-08-31
EP3539989A1 (en)	2019-09-18

Publication	Publication Date	Title
DK1994055T3 (da)	2014-08-25	Anti-5t4-antistoffer og anvendelser deraf
DK2059535T3 (da)	2014-01-13	Prlr-specifikt antistof og anvendelser deraf
DK2209806T3 (da)	2012-09-17	Anti-hepcidin-antistoffer og anvendelser deraf
DK2907827T3 (da)	2019-01-02	Humaniserede anti-faktor D-antistoffer og anvendelser deraf
DK2118140T3 (da)	2013-07-01	Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2068887T3 (da)	2014-05-19	SP35-antistoffer og anvendelser heraf
DK1904104T3 (da)	2013-11-11	SP35-antistoffer og anvendelser heraf
NO344992B1 (no)	2020-08-17	Anti-GM-CSF antistoffer og anvendelser for disse
DK2283041T3 (da)	2015-12-07	Humaniserede anti-faktor d-antistoffer og anvendelser deraf
DK2032606T3 (da)	2014-02-03	Antistoffer og immunkonjugater og anvendelser deraf
DK2328931T3 (da)	2013-09-30	Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
DK1996625T3 (da)	2011-11-28	Anti-Tat226 antistoffer og immunkonjugater
DK3124497T3 (da)	2020-05-11	Rationelt designede syntetiske antistofbiblioteker og anvendelser deraf
DK3002298T3 (da)	2019-10-28	Anti-faktor xi monoklonale antistoffer og fremgangsmåder til anvendelse deraf
DK2993187T3 (da)	2019-08-26	Antistoffer rettet mod her-3 og anvendelser deraf
DK2147096T3 (da)	2015-06-15	Modificerede faktor-VII-polypeptider og anvendelser deraf
NO20092217L (no)	2009-06-09	Agonist TrkB antistoffer og anvendelser derav
DK1896073T3 (da)	2013-06-03	Anti-il-antistoffer, sammensætninger, fremgangsmåder og anvendelser
DK3020729T3 (da)	2019-07-29	Antistoffer mod human il-22 og anvendelser deraf
DK2356270T3 (da)	2016-12-12	Kombinatoriske antistofbiblioteker og anvendelser deraf
DK2061814T3 (da)	2012-08-27	Antistoffer og immunokonjugater og anvendelse deraf.
DK1866339T3 (da)	2013-09-02	GTR-bindende molekyler og anvendelser heraf
IL196550A0 (en)	2011-08-01	Anti-il-6 monoclonal antibodies and uses thereof
DK2993186T3 (da)	2019-11-25	En monoklonal antistof og en fremgangsmåde hertil
NO20076607L (no)	2008-02-27	TWEAK - bindende antistoff